Advertisement

Some Physico-chemical Properties of Doxazosin Mesylate Polymorphic Forms and its Amorphous State

  • M. Grčman
  • F. Vrečer
  • A. Meden
Article

Abstract

Seven polymorphic modifications of doxazosin mesylate, designed as forms A, D, E, F, G, H, I, and the amorphous state were studied by thermal methods (TG and DSC), temperature resolved X-ray powder diffractometry, hot stage and scanning electron microscopy and by FT-IR spectroscopy. Amorphous form was obtained either by fast evaporation of the solvent or by fast cooling of the melt in the DSC. Polymorphs A and F were found to be stable in the temperature range from room temperature to their melting points at 277.9 and 276.5°C, respectively. Form G, which melts at 270.8°C, was found to be hygroscopic. Polymorph D undergoes irreversible solid–liquid–solid phase transition at 235.5°C to polymorph I which melts at 274.9°C. Form H, which melts at 258.0°C, was found to be unstable at high temperatures. DSC examinations revealed that form H is irreversibly transformed to polymorph F during heating above the temperature of about 240°C. The amorphous state was found to be stable at room temperature but when heating above the glass transition (T g=144.1°C) it crystallizes at 221.6°C, what leads into a mixture of polymorphic forms. The new polymorphic form designed as E was identified in the mixture. The polymorph E is converted by heating to the more stable form F. The solubilities at 25°C for forms A, and F in methanol are 3.5 and 7.7 mg mL−1and in water they are 3.8 and 6.2 mg mL−1, respectively.

amorphous state doxazosin mesylate polymorphic forms stability thermal characterization 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. J. W. Grant, Theory and origin of polymorphism, in Polymorphism in Pharmaceutical Solids, H. G. Brittain (ed.), Marcel Dekker 1999, p. 1.Google Scholar
  2. 2.
    D. Giron, J. Therm. Anal. Cal., 56 (1999) 1285.CrossRefGoogle Scholar
  3. 3.
    T. L. Threlfall, Analyst, 120 (1995) 2435.CrossRefGoogle Scholar
  4. 4.
    H. G. Brittain, J. Pharm. Sci., 86 (1997) 405.CrossRefGoogle Scholar
  5. 5.
    E. Marti and D. Giron, Chimia, 51 (1997) 747.Google Scholar
  6. 6.
    P. Klein, M. Thyes and D. Hlix, WO 99/35143 (1998).Google Scholar
  7. 7.
    I. Grafe and J. P. Morsdorf, EP 0 849 264 A1 (1996).Google Scholar
  8. 8.
    I. Grafe and J. P. Morsdorf, EP 0 849 265 A1 (1996).Google Scholar
  9. 9.
    I. Grafe and J. P. Morsdorf, EP 0 849 266 A1 (1996).Google Scholar
  10. 10.
    V. Cannata, S. Piani, C. Carrara and S. Saguati, EP 0 848 001 A1 (1997).Google Scholar
  11. 11.
    X. Liying, S. Desen and L. Shaosun, Chines. J. Med., 5 (1995) 266.Google Scholar
  12. 12.
    M. Grčman, A. S. Čurin, B. Šuštar and F. Vrečer, Farm. Vestn., 48 (1997) 292.Google Scholar

Copyright information

© Kluwer Academic Publishers/Akadémiai Kiadó 2002

Authors and Affiliations

  • M. Grčman
    • 1
  • F. Vrečer
    • 1
  • A. Meden
    • 2
  1. 1.Krka, d.d., Novo mesto, Research and Development DivisionNovo mestoSlovenia
  2. 2.Faculty of Chemistry and Chemical TechnologyUniversity of LjubljanaLjubljanaSlovenia

Personalised recommendations